News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,644 Results
Type
Article (39052)
Company Profile (279)
Press Release (646313)
Section
Business (203866)
Career Advice (1991)
Deals (35363)
Drug Delivery (85)
Drug Development (80800)
Employer Resources (168)
FDA (16088)
Job Trends (14805)
News (344547)
Policy (32437)
Tag
Academia (2530)
Alliances (49087)
Alzheimer's disease (1229)
Approvals (16020)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11538)
Biotechnology (200)
Breast cancer (120)
Cancer (1087)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (234)
Clinical research (64252)
Collaboration (388)
Compensation (200)
COVID-19 (2530)
C-suite (94)
Data (1126)
Diabetes (152)
Diagnostics (6139)
Earnings (84821)
Employer resources (146)
Events (109490)
Executive appointments (310)
FDA (16627)
Funding (353)
Gene therapy (178)
GLP-1 (577)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16303)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19141)
Metabolic disorders (402)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1481)
Obesity (232)
Opinion (179)
Patents (102)
People (56274)
Phase I (19955)
Phase II (28303)
Phase III (21099)
Pipeline (458)
Postmarket research (2554)
Preclinical (8494)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5890)
Regulatory (21525)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1302)
Startups (3562)
United States (13499)
Vaccines (549)
Weight loss (168)
Date
Today (79)
Last 7 days (681)
Last 30 days (3727)
Last 365 days (35685)
2024 (32750)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37123)
Australia (6059)
California (3331)
Canada (1295)
China (252)
Colorado (147)
Connecticut (153)
Europe (79506)
Florida (461)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2610)
Michigan (158)
Minnesota (273)
New Jersey (957)
New York (964)
North Carolina (702)
Northern California (1481)
Ohio (139)
Pennsylvania (847)
South America (1091)
Southern California (1302)
Texas (465)
Utah (90)
Washington State (362)
685,644 Results for "theradaptive inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Theradaptive Announces Peer-Reviewed Publication in Spine of Preclinical Spinal Fusion Study of OsteoAdapt™ SP
November 6, 2024
·
3 min read
BioCapital
Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human Clinical Trials
Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced it has been awarded funding from the Maryland Stem Cell Research Fund to support human clinical trials for its lead product, OsteoAdapt SP.
May 22, 2024
·
3 min read
Press Releases
THERADAPTIVE ANNOUNCES FIRST PATIENT TREATED IN OASIS CLINICAL TRIAL OF OSTEOADAPT SP FOR SPINAL FUSION
September 11, 2024
·
3 min read
Drug Development
U.S. FDA GRANTS THERADAPTIVE IDE APPROVAL FOR PHASE I/II CLINICAL TRIALS
Theradaptive, the market leader in targeted regenerative therapeutics, has gained approval from the U.S. Food and Drug Administration (FDA) for their Investigational Device Exemption (IDE) submission to begin enrolling patients into OASIS, their global Phase I/II Feasibility study in spine fusion.
February 1, 2024
·
5 min read
BioCapital
Theradaptive Awarded DOD Clinical Trial Award of up to $7.4 Million
Today, Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies
September 26, 2023
·
3 min read
BioCapital
Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund
Theradaptive, a biopharmaceutical firm pioneering advancements in targeted regenerative therapeutics, has been awarded the Manufacturing Assistance Program grant by the Maryland Stem Cell Research Fund.
July 6, 2023
·
2 min read
BioCapital
Theradaptive Closes $26 Million Series A Investment Round
Theradaptive, a biopharmaceutical company breaking new ground in targeted regenerative therapeutics, announces that it has closed a $26 million Series A funding round to advance development of its targeted regenerative therapeutics.
June 15, 2023
·
3 min read
BioCapital
Theradaptive’s Targetable Protein AMP2 Beats Spinal Fusion Standard of Care
This week, Theradaptive, a leading biotechnology company specializing in therapeutic delivery platforms, presents a new abstract demonstrating the efficacy and safety of the company’s novel AMP2 protein technology in rabbit PLF and sheep interbody fusion models.
February 9, 2023
·
3 min read
FDA
Theradaptive Secures Third FDA Breakthrough Designation for Spinal Fusion
Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion.
June 22, 2022
·
2 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
1 of 68,565
Next
